ERBB2 and breast carcinoma: A meta-analysis involving more than 11,000 breast cancer patients revealed that elevated levels of RTKs, including HER2, EGFR and FGFR, are associated with increased breast cancer aggressiveness and decreased overall and disease-free survival [7].